Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Outline of Final Research Achievements |
Heart failure is one of the leading causes of death in industrialized countries, and cardiac hypertrophy is a risk factor for heart failure. We have demonstrated that PRMT5, a protein arginine methyltransferase, is involved in the promotion of cardiac hypertrophy and the development of heart failure. These results indicate that PRMT5 is a possible molecular target for heart failure therapy.
|